|
1
|
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
|
Eur J Nucl Med Mol Imaging
|
2010
|
1.85
|
|
2
|
The clinical use of PET with (11)C-acetate.
|
Am J Nucl Med Mol Imaging
|
2011
|
1.43
|
|
3
|
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
|
J Nucl Med
|
2010
|
1.19
|
|
4
|
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
|
World J Surg Oncol
|
2007
|
1.09
|
|
5
|
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.
|
Clin Cancer Res
|
2010
|
1.09
|
|
6
|
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
|
Nucl Med Commun
|
2009
|
1.09
|
|
7
|
Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume.
|
Eur J Nucl Med Mol Imaging
|
2005
|
0.93
|
|
8
|
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.89
|
|
9
|
Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
|
Mol Imaging Biol
|
2012
|
0.89
|
|
10
|
Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
|
Eur J Radiol
|
2012
|
0.87
|
|
11
|
Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
|
Eur Urol
|
2008
|
0.85
|
|
12
|
I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report.
|
Clin Nucl Med
|
2011
|
0.82
|
|
13
|
Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT.
|
J Nucl Med
|
2011
|
0.81
|
|
14
|
Somatostatin receptor scintigraphy for bronchial carcinoid follow-up.
|
Clin Nucl Med
|
2003
|
0.76
|
|
15
|
Imaging with non-FDG PET tracers: outlook for current clinical applications.
|
Insights Imaging
|
2010
|
0.75
|